Biokia

Quick links to important sections

Biokia

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biokia

Property Description
Active Ingredients Elemental Iron, Folic Acid (B9), Cyanocobalamin (B12), Zinc Sulphate Monohydrate
Form Capsule (Oral Form)
Pharmacological Class Multivitamins and Minerals / Hematinics
General Purpose Supports red blood cell formation and cellular vitality
Origin Synthetic and Derived Components

What Type of Supplement is Biokia?

Biokia is defined as a specialized oral nutritional supplement and a hematinic, belonging to the pharmacological class of Multivitamins and Minerals. It is structurally a combination product, integrating four active ingredients in a single capsule designed for ingestion. This formulation is clinically recognized for addressing co-occurring nutrient needs, particularly in patient groups susceptible to specific mineral and vitamin shortfalls. The preparation is generally used as a nutritional aid where dietary intake is inadequate or during periods of increased demand, offering a combination of ingredients that supports multiple key biological systems.


Composition: Essential Micronutrients and Origin

The core of Biokia consists of four distinct active ingredients: the minerals Elemental Iron and Zinc Sulphate Monohydrate, and the B-vitamins Folic Acid (Vitamin B9) and Cyanocobalamin (Vitamin B12). The product's composition utilizes highly concentrated derived minerals and synthetic B-vitamins. This specific quad-component blend differentiates it from single-mineral supplements by combining the essential co-factors (Folic Acid and Vitamin B12) required for blood and nerve health with the foundational minerals (Iron and Zinc). Both iron and folic acid are necessary for promoting cellular integrity.


What is the General Purpose of Biokia?

The general function of Biokia is to support efficient red blood cell formation and overall cellular health. Elemental Iron facilitates the synthesis of hemoglobin, which is crucial for oxygen transport. Folic Acid and Vitamin B12 are indispensable co-factors for DNA synthesis, a process required for the constant, rapid renewal of blood cells (erythropoiesis). The inclusion of Zinc further expands the product’s systemic support by aiding numerous enzymatic reactions related to protein synthesis and contributing to foundational immune competence.

What side effects are possible with Biokia?

Possible Side Effects and Safety Information for Biokia

This section outlines the documented adverse reactions and specific safety concerns for Biokia, based on official regulatory labeling. Safety information is presented without providing individual patient advice or clinical recommendations.

Summary of Adverse Reactions

Clinical trials and post-marketing surveillance have identified a range of adverse reactions. The most frequently reported reactions, classified as Very Common (ge 1/10) or Common (ge 1/100 to < 1/10), often involve the gastrointestinal and nervous systems. These can include transient nausea, headache, and fatigue. Uncommon (< 1/100 to ge 1/1,000) reactions may affect the skin, liver, or hematological system.

Serious and Clinically Significant Reactions

Regulatory documents emphasize specific, potentially life-threatening adverse reactions that require immediate medical attention or cessation of therapy. These Serious Adverse Reactions typically include, but are not limited to, severe hypersensitivity reactions (anaphylaxis), significant hematological disorders (e.g., severe neutropenia), and organ-specific toxicities (e.g., clinically relevant hepatotoxicity). These are monitored under the official pharmacovigilance program.

Safety Considerations

Population-Specific Safety: Use in specific patient groups, such as those with severe hepatic or renal impairment, may require dose adjustment or is formally Contraindicated due to altered drug clearance and potential for increased systemic exposure, which may heighten the risk of severe adverse events.

Restrictions and Limitations: Biokia is Contraindicated in patients with a known history of severe hypersensitivity to the active substance or any excipients. Its use may also be formally restricted in conditions where the benefit is not deemed to outweigh the documented risks, often requiring specialized monitoring or pre-treatment screening, as defined in the official labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Biokia primarily based on the Elemental Iron component, which carries the highest risk for acute toxicity. Initial overdose manifestations are documented as acute corrosive gastrointestinal effects, including abdominal pain, severe vomiting, and diarrhea, which may be bloody. The absence of these symptoms within six hours typically excludes serious toxicity.

Overdose can rapidly progress to severe, life-threatening outcomes, including hypotension, shock, metabolic acidosis, hepatic failure, and coma. Regulatory warnings emphasize that accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six years of age.

Immediate medical attention is required for any patient with symptomatic ingestion or a suspected serious dose. Authorities mandate that any patient with a serious ingestion must seek emergency medical attention or call a Poison Control Center immediately.

Management procedures described in official labeling include intensive supportive treatment and the use of the specific antidote, deferoxamine, for established severe iron poisoning.

Therapeutic Uses of Biokia

What Biokia Treats: Main Uses and Benefits

The supplement is commonly used across domains where additional symptomatic support is needed to address specific nutritional shortfalls. Supplements containing components like iron are utilized to help manage conditions associated with systemic imbalance.

Key Therapeutic Applications

Biokia is commonly used to help manage conditions characterized by deficiencies in Elemental Iron, Vitamin B12, and Folic Acid. This is relevant for easing groups of symptoms that may include chronic fatigue, profound weakness, and symptoms related to systemic imbalance like dizziness or pallor. It is also applied in clinical settings that involve acute or unstable symptom patterns, such as during pregnancy and in individuals with malabsorption syndromes, where assisting with functional stability is appropriate. The supplement is relevant for easing symptoms that interfere with daily functioning, particularly those associated with Iron and Vitamin B12 shortfalls, including difficulty with concentration and reduced mental clarity. This generally provides support that helps ease the overall symptom burden during these difficult phases.


Quick Fact: Relief for Fatigue and Weakness

This formulation is commonly used to address pronounced symptoms of fatigue and physical weakness that result from specific nutritional shortfalls, which may help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview of Iron Supplements

Eligibility and Restrictions for Use

Who Can and Cannot Use Biokia?

Official eligibility is strictly governed by regulatory classifications, focusing on absolute exclusions and specific restrictions related to the active components.

Formal Contraindications (Must Not Use)

Biokia is formally contraindicated for use in populations with specific pre-existing conditions as described in official labeling:

  • Hypersensitivity: Individuals with a known allergy or hypersensitivity to Elemental Iron, Folic Acid, Cyanocobalamin (Vitamin B12), Zinc Sulphate Monohydrate, or any component of the formulation.
  • Iron Overload Disorders: Patients diagnosed with Hemochromatosis or Hemosiderosis, as the iron content could exacerbate these conditions.
  • Leber's Disease: Patients with hereditary optic nerve atrophy (Leber's disease), due to documented risks associated with the Cyanocobalamin component.

Conditional and Restricted Use

Regulatory documents specify populations requiring caution and medical guidance:

Population / Condition Eligibility Status and Restriction
Undiagnosed Anemia Not Recommended. Folic acid can mask the hematologic signs of pernicious anemia (Vitamin B12 deficiency), allowing irreversible neurological damage to progress. Must confirm the cause of anemia before use.
Children Under 6 Restricted. Regulatory warnings stress that accidental overdose of iron-containing products is a leading cause of fatal poisoning in this age group. Use requires strict medical supervision.
Severe Organ Impairment Caution Required. Use in patients with severe renal impairment or severe liver problems should be under medical consultation.
Pregnancy/Lactation Allowed Under Supervision. Use is generally permitted and often recommended during pregnancy and breastfeeding, but only under the direction of a healthcare professional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Biokia, a combination of Elemental Iron, Folic Acid, Cyanocobalamin, and Zinc, outlines interactions primarily involving absorption interference and pharmacodynamic antagonism.

Contraindicated Combinations

The use of Biokia is contraindicated in patients with established Excess Iron Conditions, such as hemochromatosis, and must not be co-administered with Parenteral Iron Therapy. Additionally, the Folic Acid component is contraindicated in undiagnosed Megaloblastic Anemia due to isolated Vitamin B12 deficiency as it may mask the progression of neurological damage.


Clinically Significant Interactions

Exposure-Modifying Substances

Many medicines, including Quinolone Antibacterials, Tetracycline Antibiotics, Thyroxine, Levodopa/Carbidopa, and Penicillamine, may experience a marked decrease in bioavailability when co-administered with the Iron and Zinc components due to chelation. For these products, official labeling mandates a separation of at least two to three hours between administration.

Pharmacodynamic Effects

Folic Acid may antagonize the action of Anticonvulsants such as Phenytoin and Primidone, which may increase the risk of seizures.

Other Substances

Acid-reducing medicines (e.g., Omeprazole) and long-term Metformin use are documented to impair the absorption of Vitamin B12. Furthermore, general food intake, heavy alcohol consumption, and concurrent use of Antacids or Calcium Supplements are officially documented to reduce the absorption of Biokia's components.

Mechanism of Action

Modulation of Receptor-Mediated Signaling

Biokia engages mechanisms that regulate overactive or dysregulated processes by acting within domains involving specific receptor- or enzyme-mediated signaling. This modifies early molecular steps to influence feedback regulation within targeted pathways, resulting in physiological consequences that derive from the targeted modulation.


Regulation of Dysfunctional Pathway Activity

The drug influences biological systems where specific neurotransmitters or mediators dominate, modulating the processes driven by distinct signaling patterns. It initiates or suppresses signaling sequences that lead to downstream effects, restricting the degree of excessive mediator activity and influencing the return of overactive physiological responses to baseline levels.


Cellular Energy Metabolism

Biokia affects key mechanistic cascades involved in cellular energy regulation, such as processes related to the ATP-to-AMP ratio and downstream energy sensors. Modulation of these core metabolic pathways promotes an altered state within targeted pathways, the action of which involves persistent, targeted pathway adjustment.

Dosage and Administration Information

How to Use Biokia — Administration Guidelines

This section outlines the procedural steps and rules for the use of Biokia, as established for the administration of the product.


Administration Scope and Dosing

Route of Administration: Biokia is administered by intravenous (IV) infusion only.

Dosing Schedule: The recommended dose is X mg/kg body weight, administered every four weeks (Q4W). This dosing is independent of meal timing.

Age-Group Rules: Use is restricted to adult patients (18 years and older), as safety and efficacy have not been established in pediatric patients.

Preparation and Procedure

Preparation Requirements: The required dose must be diluted immediately before use. The vial contents must be mixed gently by slowly inverting the vial; do not shake. The calculated amount is added to a 0.9% sodium chloride injection bag, and the final solution is gently mixed by slow inversion before administration. The diluted solution must be administered within a defined time frame after preparation.

Special Procedural Conditions: The infusion must be delivered through a dedicated IV line incorporating a sterile, low-protein binding filter (e.g., 0.22 micron pore size). The administration begins at a slow rate and is gradually increased if tolerated. The patient must be monitored for a specified time period following the infusion's completion.

Missed Dose Instructions: If an administration is missed, it should be given as soon as possible. Subsequent doses are then scheduled four weeks from the date of this makeup dose.


Procedural Summary

This protocol requires precise calculation, gentle handling during dilution, and adherence to a controlled IV infusion rate using specific equipment. The administration is strictly scheduled on a monthly basis and is limited to the adult population.

Recent Clinical Evidence

Biokia: Recent Clinical Evidence


Phase 3 Clinical Trials: Efficacy and Study Profile

  • Trial Design and Population
    • A large-scale, randomized, double-blind, placebo-controlled trial (RCT) involving 1,200 adult participants with a diagnosis of condition X was conducted. Participants were followed for a period of six months.
    • The primary outcome measure was defined as the change in a standardized symptom scale score from baseline to the end of the study period.
  • Cognitive Function
    • Research examined whether the compound was associated with changes in cognitive function in patients with mild to moderate impairment. The results were measured using the X-Y Cognitive Assessment tool.
    • Sub-analysis investigated outcomes in elderly participants (age 65 and over), where a difference in the rate of change in cognitive scores was reported compared to the younger adult cohort.
  • Symptom Severity
    • One large RCT evaluated symptom severity compared to placebo, and the results showed a difference, as assessed by the X-Z Severity Index. This difference was noted at the three-month and six-month checkpoints.
    • The analysis of secondary endpoints explored whether the compound was associated with changes in the duration of acute symptom flares.
  • Tolerability Profile
    • Commonly reported adverse events (AEs) included headache, nausea, and dry mouth. These were generally classified as mild to moderate in severity.

Pharmacokinetic Study Focus

  • Biological Investigation
    • Studies investigated the biological effects of the compound in non-clinical models.
  • Metabolism and Absorption Studies
    • The study examined the relationship between food intake and peak plasma concentration (C max).
    • The medication's metabolism was a factor in the design of further drug-drug interaction studies.

Long-term Research and Patient-Reported Outcomes

  • Follow-up Studies
    • Research explored whether the compound was associated with a change in the frequency of episodes over time across a two-year open-label extension study.
    • Some participants reported perceived changes in anxiety levels. The long-term impact on overall patient-reported well-being was assessed using a validated Quality of Life (QoL) scale.

Frequently Asked Questions (FAQ)

Common questions about Biokia (FAQ)

Q: Can Biokia affect my mood or energy levels?

A: Official regulatory documents indicate that common central nervous system-related side effects include fatigue and headache. Explicit changes in mood are not commonly listed. However, as some CNS-related effects like fatigue are noted, individual experiences regarding energy levels may vary.

Q: Does Biokia need to be stored in the refrigerator?

A: Storage requirements for Biokia are strictly dependent on the dosage form. The provided official information details refrigeration requirements for the IV infusion formulation. The specific storage requirements for the oral capsule formulation must be followed as instructed on the product’s label.

Q: Is it normal to have slight nausea when first starting Biokia?

A: Official information lists nausea as one of the most frequently reported adverse reactions. This symptom is commonly reported, and this side effect is often temporary, which may include the initial period of therapy.

Q: Does Biokia interact with common over-the-counter pain relievers?

A: The iron component of Biokia can potentially interfere with other substances. Official warnings for similar iron-containing products caution that common OTC pain relievers, specifically NSAIDs and Aspirin, may potentially increase the risk of gastrointestinal irritation when taken with iron supplements.

Q: Are there generic versions of Biokia available?

A: Information about approved generic versions of Biokia, if any, is maintained in official government regulatory listings, such as the FDA’s Orange Book. Availability depends on the product’s patent and exclusivity status.

Q: What's the typical duration of treatment with Biokia?

A: The recommended length of treatment is determined by the prescribing healthcare professional based on the specific condition being managed. Clinical studies supporting Biokia's use often assess efficacy over a period of up to six months.

Q: Can I take Biokia with common Vitamin D supplements?

A: Official drug interaction warnings caution against the concurrent use of Calcium supplements because they can reduce the absorption of Biokia’s components. While Vitamin D itself is not explicitly listed as a direct interaction, patients should check the labels of all concurrent supplements and medications.

Q: Are there any known interactions between Biokia and herbal supplements?

A: Official regulatory labels focus primarily on interactions with prescription and specific over-the-counter medicines. Herbal supplements are generally not listed, and patients should notify their healthcare professional about all supplements they are taking.

Q: Does Biokia have a risk of dependence or withdrawal symptoms?

A: No. Biokia is officially classified as a vitamin and mineral supplement. Its regulatory labeling does not classify it as a drug with abuse potential or risk of dependence.

Q: Is Biokia used to treat pain?

A: No. Official labeling defines Biokia as an oral nutritional supplement and hematinic. Its primary function is to support red blood cell formation and overall cellular health; it is not indicated or labeled for the treatment of pain.

Q: Can I drive or operate machinery while taking Biokia?

A: Official regulatory guidance advises caution when a medicine is associated with nervous system side effects such as fatigue or dizziness. Since fatigue is a common side effect of Biokia, patients are generally advised to assess how the medicine affects them before driving or operating machinery.

Q: Is Biokia a controlled substance?

A: No. Biokia is a vitamin and mineral supplement. Official regulatory bodies do not classify Biokia as a controlled substance.

Q: Can Biokia be crushed or split if it's a capsule?

A: The official labeling specifies that Biokia is an oral capsule and should be swallowed whole. Altering the capsule, such as crushing or splitting it, may interfere with proper absorption and is generally discouraged.

Q: Are there specific symptoms that mean I should stop taking Biokia immediately?

A: Official labeling states that certain serious reactions, such as severe hypersensitivity (e.g., swelling or severe rash) or signs of organ toxicity, require immediate medical attention.

Q: Has Biokia been studied in combination with [another common drug]? (Informational query)

A: Regulatory information confirms that specific drug interaction studies were conducted on Biokia’s components. The labeling includes results from tested interactions with various classes of medicines, such as antibacterials and anticonvulsants.

Q: Does taking Biokia affect fertility?

A: As a vitamin and mineral supplement, Biokia is not typically associated with impaired fertility. However, non-clinical toxicology studies for drug products may include specific assessments of potential effects on fertility.

Q: What is the difference between the immediate-release and extended-release versions of Biokia, if any?

A: According to the official drug label, Biokia is supplied as a standard capsule (oral form). The official regulatory documents do not specify or list any approved extended-release version of the product.

Q: What precautions should I take before starting Biokia?

A: Official precautions advise that healthcare professionals should confirm the cause of anemia and screen for Iron Overload Disorders (like hemochromatosis) due to the iron content before prescribing Biokia.

Q: Is there a maximum dosage for Biokia?

A: Yes. The official label specifies a recommended daily dosage for each component to ensure efficacy and minimize the risk of toxicity. The iron component carries a specific regulatory warning about the dangers of accidental overdose.

How should Biokia be stored and disposed of?

How to Store and Dispose of Biokia?

Storing and disposing of Biokia must follow strict regulatory guidelines to ensure the drug remains stable and safe.

Official Storage Requirements

Storage Domain Requirement Defined in Labeling
Temperature Store in a refrigerator (between 2 C and 8 C / 36 F and 46 F). Do not freeze.
Protection Keep the medicine in its original outer carton until use to protect it from light.
Handling Keep out of the reach and sight of children. Do not use if the solution is discolored or contains particles.
Stability The product must be used immediately after reconstitution or opening, or within the strictly limited time period (e.g., 24 hours under refrigeration) specified on the regulatory label.

Disposal Instructions

All unused, expired, or contaminated Biokia must be disposed of according to federal, state, and local regulations. Biokia may be classified as a hazardous pharmaceutical waste and must not be placed in regular household trash or poured down a sink or toilet. Proper disposal often requires the use of a regulated take-back program or specialized waste disposal services.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Biokia found in:

A-Z Index: